0
Original Research: PULMONARY HYPERTENSION |

Transition From IV Epoprostenol to Subcutaneous Treprostinil in Pulmonary Arterial Hypertension*: A Controlled Trial

Melvyn Rubenfire, MD; Vallerie V. McLaughlin, MD, FCCP; Roblee P. Allen, MD, FCCP; Greg Elliott, MD; Myung H. Park, MD; Michael Wade, PhD; Robert Schilz, DO, PhD
Author and Funding Information

Affiliations: *From the University of Michigan Health System (Drs. Rubenfire and McLaughlin), Ann Arbor, MI; UC Davis Medical Center (Dr. Allen), Sacramento, CA; LDS Hospital and the University of Utah (Dr. Elliot), Salt Lake City, UT; University of Maryland School of Medicine (Dr. Park), Baltimore, MD; United Therapeutics Corporation (Dr. Wade), Research Triangle Park, NC; and University Hospitals of Cleveland (Dr. Schilz), Cleveland, OH.,  For the Treprostinil Phase 4 Study Group: R. Clayton, RN, and S. McDevitt, RN; MSN, University of Michigan, Ann Arbor, MI; L. Latham, RN, and L. Slaughter RN, University Hospitals of Cleveland, Cleveland, OH; A. Hoso, RN, UC Davis Medical Center, Sacramento, CA; N. Kitterman, RN, LDS Hospital, Salt Lake City, UT; B. Harris, RN, and M. Franklin, LNP, Oschner Clinic, New Orleans, LA; J. Sigman, C. Arneson, M.Stat, W. DellaMaestra, S. McSwain, D. Preston, DVM, and R. Jeffs, PhD, United Therapeutics Corporation, Research Triangle Park, NC.

Correspondence to: Melvyn Rubenfire, MD, University of Michigan, 24 Frank Lloyd Wright Dr, Ann Arbor, MI 48106-0363; e-mail: mrubenfi@umich.edu



Chest. 2007;132(3):757-763. doi:10.1378/chest.06-2118
Text Size: A A A
Published online

Background: We determined the relative efficacy of subcutaneous (SC) treprostinil in stable World Health Organization class II and III patients transitioned from IV epoprostenol.

Methods: This was an 8-week, multicenter, randomized study in which patients were transitioned from IV epoprostenol to SC treprostinil or placebo over a period of up to 14 days and monitored carefully during and after the transition period for signs of deterioration. Patients with clinical deterioration were returned promptly to epoprostenol. Placebo or SC treprostinil doses were titrated in response to symptoms. Time to adjudicated clinical deterioration was compared between treatment groups, and exercise capacity, symptoms of disease, and safety were assessed throughout the study.

Results: Twenty-two patients were enrolled and completed the study. Seven of 8 patients (88%) withdrawn to placebo had clinical deterioration, while only 1 of 14 patients (7%) withdrawn to SC treprostinil had clinical deterioration (p = 0.00023 based on a treatment comparison of time to deterioration). Analyses of exercise capacity and symptoms strongly supported the efficacy of SC treprostinil in epoprostenol-treated patients. Adverse events consisted of painful infusion site reactions and anticipated prostacyclin side effects.

Conclusions: SC treprostinil is effective in pulmonary arterial hypertension and prevents clinical deterioration and maintains functional status in patients transitioned from epoprostenol.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543